ZA200509904B - Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight - Google Patents
Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight Download PDFInfo
- Publication number
- ZA200509904B ZA200509904B ZA200509904A ZA200509904A ZA200509904B ZA 200509904 B ZA200509904 B ZA 200509904B ZA 200509904 A ZA200509904 A ZA 200509904A ZA 200509904 A ZA200509904 A ZA 200509904A ZA 200509904 B ZA200509904 B ZA 200509904B
- Authority
- ZA
- South Africa
- Prior art keywords
- patient
- treatment
- overweight
- composition
- asenapine
- Prior art date
Links
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 title claims description 32
- 229960005245 asenapine Drugs 0.000 title claims description 30
- 201000000980 schizophrenia Diseases 0.000 title claims description 25
- 239000003814 drug Substances 0.000 claims description 21
- 239000000164 antipsychotic agent Substances 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 235000019786 weight gain Nutrition 0.000 claims description 12
- 230000004584 weight gain Effects 0.000 claims description 12
- 230000001965 increasing effect Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 206010033307 Overweight Diseases 0.000 description 27
- 229940079593 drug Drugs 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 208000021017 Weight Gain Diseases 0.000 description 10
- 229940068196 placebo Drugs 0.000 description 10
- 239000000902 placebo Substances 0.000 description 10
- 229960001534 risperidone Drugs 0.000 description 10
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 10
- 208000008589 Obesity Diseases 0.000 description 8
- 235000020824 obesity Nutrition 0.000 description 8
- 230000037396 body weight Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000000561 anti-psychotic effect Effects 0.000 description 3
- 239000003693 atypical antipsychotic agent Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000000698 schizophrenic effect Effects 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 2
- 230000009798 acute exacerbation Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 229940127236 atypical antipsychotics Drugs 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229960005017 olanzapine Drugs 0.000 description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- 206010001540 Akathisia Diseases 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 101100369915 Drosophila melanogaster stas gene Proteins 0.000 description 1
- 241000692870 Inachis io Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
- 230000002932 anti-schizophrenic effect Effects 0.000 description 1
- 235000021053 average weight gain Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- ZTHJULTYCAQOIJ-WXXKFALUSA-N quetiapine fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 ZTHJULTYCAQOIJ-WXXKFALUSA-N 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940035004 seroquel Drugs 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229960000652 sertindole Drugs 0.000 description 1
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 description 1
- 230000011273 social behavior Effects 0.000 description 1
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
- 229950001675 spiperone Drugs 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- 230000015883 synaptic transmission, dopaminergic Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03101721 | 2003-06-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200509904B true ZA200509904B (en) | 2006-12-27 |
Family
ID=33547705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200509904A ZA200509904B (en) | 2003-06-12 | 2005-12-06 | Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20060128688A1 (da) |
| EP (1) | EP1635820B1 (da) |
| JP (1) | JP2006527238A (da) |
| KR (1) | KR20060020664A (da) |
| CN (1) | CN1816335A (da) |
| AR (1) | AR044675A1 (da) |
| AT (1) | ATE395914T1 (da) |
| AU (1) | AU2004246820B2 (da) |
| BR (1) | BRPI0411237A (da) |
| CA (1) | CA2528365A1 (da) |
| CY (1) | CY1110366T1 (da) |
| DE (1) | DE602004013966D1 (da) |
| DK (1) | DK1635820T3 (da) |
| ES (1) | ES2305829T3 (da) |
| IL (1) | IL172397A (da) |
| NO (1) | NO20055884L (da) |
| NZ (1) | NZ544018A (da) |
| PL (1) | PL1635820T3 (da) |
| PT (1) | PT1635820E (da) |
| RU (1) | RU2352336C2 (da) |
| SI (1) | SI1635820T1 (da) |
| TW (1) | TWI327915B (da) |
| WO (1) | WO2004110437A1 (da) |
| ZA (1) | ZA200509904B (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602006000080T2 (de) * | 2005-04-07 | 2008-05-15 | N.V. Organon | Kristallform von Asenapinmaleat |
| US7741358B2 (en) | 2005-04-14 | 2010-06-22 | N.V. Organon | Crystal form of asenapine maleate |
| ES2769286T3 (es) | 2016-12-20 | 2020-06-25 | Lts Lohmann Therapie Systeme Ag | Sistema terapéutico transdérmico que contiene asenapina |
| WO2018115010A1 (en) | 2016-12-20 | 2018-06-28 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
| ES2881783T3 (es) | 2017-06-26 | 2021-11-30 | Lts Lohmann Therapie Systeme Ag | Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona |
| CA3101420A1 (en) | 2018-06-20 | 2019-12-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| CN112533593A (zh) | 2018-06-20 | 2021-03-19 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
| WO2020106330A1 (en) * | 2018-07-18 | 2020-05-28 | Pillsy, Inc. | Smart drug delivery and monitoring device, kit, and method of use for pill compounds |
| JP7569492B2 (ja) | 2019-12-11 | 2024-10-18 | コーセプト セラピューティクス， インコーポレイテッド | 抗精神病薬誘発性体重増加のミリコリラントによる治療方法 |
| RU2756614C1 (ru) * | 2021-04-07 | 2021-10-04 | Федеральное государственное бюджетное научное учреждение «Томский национальный исследовательский медицинский центр Российской академии наук» (Томский НИМЦ) | Способ поддержки принятия врачебных решений выбора антипсихотической терапии у больных шизофренией с целью профилактики акатизии |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4099224B2 (ja) * | 1994-03-02 | 2008-06-11 | ナームローゼ・フエンノートチヤツプ・オルガノン | 舌下又はバッカル医薬組成物 |
| US5496831A (en) * | 1994-05-13 | 1996-03-05 | The General Hospital Corporation | Inhibition of insulin-induced adiposis |
| JP2004517112A (ja) * | 2001-01-02 | 2004-06-10 | ファルマシア・アンド・アップジョン・カンパニー | 新規薬物コンビネーション |
-
2004
- 2004-06-03 TW TW093116017A patent/TWI327915B/zh not_active IP Right Cessation
- 2004-06-09 AT AT04766041T patent/ATE395914T1/de active
- 2004-06-09 DE DE602004013966T patent/DE602004013966D1/de not_active Expired - Lifetime
- 2004-06-09 RU RU2006101061/14A patent/RU2352336C2/ru not_active IP Right Cessation
- 2004-06-09 US US10/560,554 patent/US20060128688A1/en not_active Abandoned
- 2004-06-09 ES ES04766041T patent/ES2305829T3/es not_active Expired - Lifetime
- 2004-06-09 PL PL04766041T patent/PL1635820T3/pl unknown
- 2004-06-09 DK DK04766041T patent/DK1635820T3/da active
- 2004-06-09 EP EP04766041A patent/EP1635820B1/en not_active Expired - Lifetime
- 2004-06-09 BR BRPI0411237-7A patent/BRPI0411237A/pt not_active IP Right Cessation
- 2004-06-09 SI SI200430755T patent/SI1635820T1/sl unknown
- 2004-06-09 CN CNA200480018591XA patent/CN1816335A/zh active Pending
- 2004-06-09 CA CA002528365A patent/CA2528365A1/en not_active Abandoned
- 2004-06-09 WO PCT/EP2004/051069 patent/WO2004110437A1/en not_active Ceased
- 2004-06-09 NZ NZ544018A patent/NZ544018A/en not_active IP Right Cessation
- 2004-06-09 PT PT04766041T patent/PT1635820E/pt unknown
- 2004-06-09 KR KR1020057023646A patent/KR20060020664A/ko not_active Ceased
- 2004-06-09 AU AU2004246820A patent/AU2004246820B2/en not_active Ceased
- 2004-06-09 JP JP2006516141A patent/JP2006527238A/ja active Pending
- 2004-06-11 AR ARP040102026A patent/AR044675A1/es unknown
-
2005
- 2005-12-06 ZA ZA200509904A patent/ZA200509904B/en unknown
- 2005-12-06 IL IL172397A patent/IL172397A/en not_active IP Right Cessation
- 2005-12-12 NO NO20055884A patent/NO20055884L/no not_active Application Discontinuation
-
2008
- 2008-06-24 CY CY20081100659T patent/CY1110366T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20060128688A1 (en) | 2006-06-15 |
| EP1635820A1 (en) | 2006-03-22 |
| PT1635820E (pt) | 2008-06-17 |
| ES2305829T3 (es) | 2008-11-01 |
| SI1635820T1 (sl) | 2008-08-31 |
| BRPI0411237A (pt) | 2006-07-11 |
| NO20055884L (no) | 2006-01-03 |
| PL1635820T3 (pl) | 2008-10-31 |
| KR20060020664A (ko) | 2006-03-06 |
| HK1084894A1 (en) | 2006-08-11 |
| ATE395914T1 (de) | 2008-06-15 |
| DK1635820T3 (da) | 2008-09-08 |
| DE602004013966D1 (de) | 2008-07-03 |
| EP1635820B1 (en) | 2008-05-21 |
| AU2004246820A1 (en) | 2004-12-23 |
| CY1110366T1 (el) | 2014-04-09 |
| TW200501946A (en) | 2005-01-16 |
| CA2528365A1 (en) | 2004-12-23 |
| IL172397A0 (en) | 2006-04-10 |
| CN1816335A (zh) | 2006-08-09 |
| IL172397A (en) | 2010-06-16 |
| RU2006101061A (ru) | 2006-07-27 |
| TWI327915B (en) | 2010-08-01 |
| AU2004246820B2 (en) | 2009-10-01 |
| NZ544018A (en) | 2008-07-31 |
| JP2006527238A (ja) | 2006-11-30 |
| AR044675A1 (es) | 2005-09-21 |
| RU2352336C2 (ru) | 2009-04-20 |
| WO2004110437A1 (en) | 2004-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101841442B1 (ko) | 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법 | |
| HK1209323A1 (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression | |
| US20120010242A1 (en) | Low dose pipamperone in treating mood disorders | |
| US6835728B2 (en) | Drug combination for the treatment of depression and related disorders comprising mirtazapine | |
| AU2004246820B2 (en) | Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight | |
| EP4091607A1 (en) | Methods for treating central nervous system disorders with muscarinic receptor activator xanomeline and antipsychotics | |
| CN117177741A (zh) | 用于治疗睡眠呼吸暂停的去甲肾上腺素再摄取抑制剂和大麻素的组合 | |
| TW201841635A (zh) | 用於治療抑鬱症之組合物及方法 | |
| US20220370454A1 (en) | Methods for treating central nervous system disorders with muscarinic receptor activation and antipsychotics | |
| EP2236138A1 (en) | Low dose pipamperone in treating mood and anxiety disorders | |
| WO2010112530A1 (en) | Pipamperone and a second agent in treating mood and anxiety disorders | |
| TW200821296A (en) | Use of sertindole for the preventive treatment of suicidal behaviour | |
| HK1084894B (en) | Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight | |
| MXPA05013580A (en) | Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight | |
| Ratan et al. | Capgras syndrome in postpartum depression | |
| HK40084241A (en) | Methods for treating central nervous system disorders with muscarinic receptor activator xanomeline and antipsychotics | |
| HK40071665B (zh) | 在痴呆患者中治疗行为和精神症状 | |
| Farragher et al. | Delayed onset of extrapyramidal side-effects on combining paroxetine with risperidone | |
| Home | Zolpidem Oral Zolpidem tartrate, a type A γ-aminobutyric acid (GABA A)-receptor positive modulator of the imidazopyridine class, is a sedative and hypnotic agent structurally unrelated to the benzodiazepines and other sedative and hypnotic agents.[Brand Name: Ambien, Ambien CR Class: Non-benzodiazepine Hypnotics (28: 24.44) | |
| WO2012072665A1 (en) | Compositions comprising pipamperone and serotonin antagonist reuptake inhibitors |